Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
8/26/25 | Eli Lilly (LLY) | Orforglipron for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
8/25/25 | argenx (ARGX) | Vyvgart for Myasthenia Gravis (MG) | Subscribers Only | Subscribers Only | Subscribers Only |
8/21/25 | NicOx (COX) | NCX 470 for Glaucoma / Ocular Hypertension (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
8/19/25 | Viking Therapeutics (VKTX) | VK2735 for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
8/18/25 | Reunion | RE104 for Postpartum Depression (PPD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |